SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research ("SMR"), being held on October 10-13, 2024 in New Orleans, Louisiana. Th ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close of $12.63. This places CATX 31.44% below its 52-week high of $19.05 and 493.37% above its 52-week low of $2.20. Trading volume was 204,700 shares, 23.9% of the average daily volume of 856,527. Wall Street Analysts Forecast Based on the one-year price targets offered by 8 analysts, the average target price for Pe ...

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM"), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the ...

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences. Morgan Stanley 22nd Annual Global Healthcare Conference Date: September 6, 2024 Locat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-33407 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------- ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Perspective Therapeutics (CATX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Perspective Therapeutics is a member of our Medical group, which includes 1019 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gau ...

Financial Performance - The net loss for the three months ended March 31, 2024, was $12.3 million, or $0.02 loss per share, compared to a net loss of $0.4 million, or $0.00 per share, for the same period in 2023[21]. - The net loss from continuing operations was $11,214,000 for the three months ended June 30, 2024, compared to a loss of $9,486,000 in the same period last year[29]. - Total operating expenses for the quarter ended March 31, 2024, were $13.3 million, an increase of approximately 33% compared to $10.0 million for the same period in 2023[21]. - Total operating expenses increased to $14,789,000 for the three months ended June 30, 2024, compared to $10,342,000 in the prior year, reflecting a 43% rise[29]. Research and Development - Research and development expenses increased by approximately 127% to $7.5 million for the three months ended March 31, 2024, compared to $3.3 million for the same period in 2023[20]. - Research and development expenses for the three months ended June 30, 2024, were $9,275,000, up 72% from $5,370,000 in the same period last year[29]. - The company initiated dosing of nine patients in its Phase 1/2a study of [212Pb]VMT-α-NET, with seven patients receiving 185 MBq (5 mCi) of the treatment[3]. - The company is conducting a multi-center, open-label dose escalation study of [212Pb]VMT01 in patients with progressive MC1R-positive metastatic melanoma[8]. - The company entered a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb]VMT01 in combination with nivolumab[9]. - The company has applied for a Phase I tranche of a $400,000 grant from the National Institutes of Health to support the development of its pre-targeting program[15]. Cash and Investments - Cash, cash equivalents, and short-term investments as of March 31, 2024, were $180.6 million, compared to $9.2 million on December 31, 2023[22]. - Cash, cash equivalents, and short-term investments increased to $292,869,000 as of June 30, 2024, compared to $9,238,000 on December 31, 2023[27]. Company Growth and Future Plans - The company raised $177.2 million in gross proceeds through various financing transactions and an additional $49.5 million subsequent to March 31, 2024[1]. - Total assets rose to $385,919,000 from $97,891,000, indicating significant growth[27]. - The company expects to submit the VMT01 study amendment in the second quarter of 2024, with the first combination cohort anticipated to open shortly thereafter[25]. - The company plans to file an IND for PSV359 in late 2024, with a Phase I study expected to commence in 2025 if the study proceeds[25]. - The Somerset facility's filing is expected in the second half of 2024, aligning with the company's expansion plans[25]. - The company anticipates an increase in general and administrative expenses as it expands its headcount to support ongoing development[25]. - The company projects sufficient funding for operations and capital investments into the first quarter of 2026[25]. Administrative Expenses - General and administrative expenses decreased by approximately 12% to $5.9 million for the three months ended March 31, 2024, compared to $6.7 million for the same period in 2023[21].

Panel Discussion - Nuke 'em From Orbit: Radiotherapy Time: 9:30am ET SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as not ...

Panel Discussion - Nuke 'em From Orbit: Radiotherapy Time: 9:30am ET About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics ...